3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Conditions
Multiple Myeloma
81
Neoplasms, Plasma Cell
27
Neoplasms
13
Brain Neoplasms
11
Prostatic Neoplasms
10
Central Nervous System Neoplasms
10
Melanoma
9
Leukemia
9
Glioblastoma
8
Gliosarcoma
7
Glioma
7
Leukemia, Lymphocytic, Chronic, B-Cell
6
Carcinoma, Hepatocellular
6
Recurrence
5
Myeloproliferative Disorders
5
Myelodysplastic Syndromes
5
Lymphoma, Mantle-Cell
5
Lung Neoplasms
5
Waldenstrom Macroglobulinemia
4
Sarcoma
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Immunoglobulin Light-chain Amyloidosis
4
Carcinoma, Renal Cell
4
Uveal Melanoma
3
Oligodendroglioma
3
Neuroblastoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Interventions
Vincristine
10
Filgrastim
10
Cyclophosphamide
10
Doxorubicin
8
Etoposide
7
Radiotherapy
6
Dactinomycin
6
Carboplatin
6
Granulocyte Colony-Stimulating Factor
5
Topotecan
4
Polymerase Chain Reaction
4
Gene Expression Profiling
4
sargramostim
3
Temozolomide
3
Reverse Transcriptase Polymerase Chain Reaction
3
Peripheral Blood Stem Cell Transplantation
3
Melphalan
3
Itraconazole
3
Irinotecan
3
Ifosfamide
3
DNA Methylation
3
Cisplatin
3
Busulfan
3
liposomal amphotericin B
2
ixabepilone
2
X-Rays
2
Voriconazole
2
Therapeutics
2
Stem Cell Transplantation
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Wilms Tumor
×
Thalidomide
×
Clear all
NCT01661400
2024-01-31
ASCR
Washington University School of Medicine
Phase 1
Completed
14 enrolled